Neuropsychological Assessment Should Always be Considered in Myotonic Dystrophy Type 2.
Journal
Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology
ISSN: 1543-3641
Titre abrégé: Cogn Behav Neurol
Pays: United States
ID NLM: 101167278
Informations de publication
Date de publication:
03 03 2021
03 03 2021
Historique:
received:
09
11
2019
accepted:
21
07
2020
entrez:
2
3
2021
pubmed:
3
3
2021
medline:
22
5
2021
Statut:
epublish
Résumé
Myotonic dystrophies (DMs) are hereditary, multisystem, slowly progressive myopathies. One of the systems they affect is the CNS. In contrast to the well-established cognitive profile of myotonic dystrophy type 1 (DM1), only a few studies have investigated cognitive dysfunction in individuals with myotonic dystrophy type 2 (DM2), and their findings have been inconsistent. To identify the most commonly affected cognitive domains in individuals with DM2, we performed a formal comprehensive review of published DM2 studies. Using the terms "myotonic dystrophy type 2" AND "cognitive deficits," "cognitive," "cognition," "neuropsychological," "neurocognitive," and "neurobehavioral" in all fields, we conducted an advanced search on PubMed. We read and evaluated all of the available original research articles (13) and one case study, 14 in total, and included them in our review. Most of the research studies of DM2 reported primary cognitive deficits in executive functions (dysexecutive syndrome), memory (short-term nonverbal, verbal episodic memory), visuospatial/constructive-motor functions, and attention and processing speed; language was rarely reported to be affected. Based on the few neuroimaging and/or multimodal DM2 studies we could find, the cognitive profile of DM2 is associated with brain abnormalities in several secondary and high-order cortical and subcortical regions and associative white matter tracts. The limited sample size of individuals with DM2 was the most prominent limitation of these studies. The multifaceted profile of cognitive deficits found in individuals with DM2 highlights the need for routine neuropsychological assessment at both baseline and follow-up, which could unveil these individuals' cognitive strengths and deficits.
Identifiants
pubmed: 33652465
doi: 10.1097/WNN.0000000000000263
pii: 00146965-202103000-00002
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-10Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Abrahams S, Newton J, Niven E, et al. 2014. Screening for cognition and behaviour changes in ALS. Amyotroph Lateral Scler Frontotemporal Degener. 15:9–14. doi:10.3109/21678421.2013.805784
doi: 10.3109/21678421.2013.805784
Ates S, Deistung A, Schneider R, et al. 2019. Characterization of iron accumulation in deep gray matter in myotonic dystrophy type 1 and 2 using quantitative susceptibility mapping and R2* relaxometry: a magnetic resonance imaging study at 3 tesla [published online December 13]. Front Neurol. 10:1320. doi:10.3389/fneur.2019.01320
doi: 10.3389/fneur.2019.01320
Bajrami A, Azman F, Yayla V, et al. 2017. MRI findings and cognitive functions in a small cohort of myotonic dystrophy type 1: retrospective analyses. Neuroradiol J. 30:23–27. doi:10.1177/1971400916678223
doi: 10.1177/1971400916678223
Baldanzi S, Cecchi P, Fabbri S, et al. 2016. Relationship between neuropsychological impairment and grey and white matter changes in adult-onset myotonic dystrophy type 1. Neuroimage Clin. 12:190–197. doi:10.1016/j.nicl.2016.06.011
doi: 10.1016/j.nicl.2016.06.011
Bede P, Omer T, Finegan E, et al. 2018. Connectivity-based characterisation of subcortical grey matter pathology in frontotemporal dementia and ALS: a multimodal neuroimaging study. Brain Imaging Behav. 12:1696–1707. doi:10.1007/s11682-018-9837-9
doi: 10.1007/s11682-018-9837-9
Cabada T, Iridoy M, Jericó I, et al. 2017. Brain involvement in myotonic dystrophy type 1: a morphometric and diffusion tensor imaging study with neuropsychological correlation. Arch Clin Neuropsychol. 32:401–412. doi:10.1093/arclin/acx008
doi: 10.1093/arclin/acx008
Chaytor N, Schmitter-Edgecombe M. 2003. The ecological validity of neuropsychological tests: a review of the literature on everyday cognitive skills. Neuropsychol Rev. 13:181–197. doi:10.1023/b:nerv.0000009483.91468.fb
doi: 10.1023/b:nerv.0000009483.91468.fb
Christidi F, Karavasilis E, Rentzos M, et al. 2018. Clinical and radiological markers of extra-motor deficits in amyotrophic lateral sclerosis [published online November 22]. Front Neurol. 9:1005. doi:10.3389/fneur.2018.01005
doi: 10.3389/fneur.2018.01005
Elamin M, Pinto-Grau M, Burke T, et al. 2017. Identifying behavioural changes in ALS: validation of the Beaumont Behavioural Inventory (BBI). Amyotroph Lateral Scler Frontotemporal Degener. 18:68–73. doi:10.1080/21678421.2016.1248976
doi: 10.1080/21678421.2016.1248976
Folstein MF, Folstein SE, McHugh PR. 1975. “Mini-mental state”. a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 12:189–198. doi:10.1016/0022-3956(75)90026-6
doi: 10.1016/0022-3956(75)90026-6
Gaul C, Schmidt T, Windisch G, et al. 2006. Subtle cognitive dysfunction in adult onset myotonic dystrophy type 1 (DM1) and type 2 (DM2). Neurology. 67:350–352. doi:10.1212/01.wnl.0000225180.27833.c1
doi: 10.1212/01.wnl.0000225180.27833.c1
Gliem C, Minnerop M, Roeske S, et al. 2019. Tracking the brain in myotonic dystrophies: a 5-year longitudinal follow-up study. PloS One. 14:e0213381. doi:10.1371/journal.pone.0213381
doi: 10.1371/journal.pone.0213381
Klein OA, Drummond A, Mhizha-Murira JR, et al. 2017. Effectiveness of cognitive rehabilitation for people with multiple sclerosis: a meta-synthesis of patient perspectives. Neuropsychol Rehabil. 29:491–512. doi:10.1080/09602011.2017.1309323
doi: 10.1080/09602011.2017.1309323
Krogias C, Bellenberg B, Prehn C, et al. 2015. Evaluation of CNS involvement in myotonic dystrophy type 1 and type 2 by transcranial sonography. J Neurol. 262:365–374. doi:10.1007/s00415-014-7566-6
doi: 10.1007/s00415-014-7566-6
Lezak MD, Howieson DB, Bigler ED, et al. 2012. Neuropsychological Assessment. 5th ed. New York, New York: Oxford University Press.
Mathuranath PS, Nestor PJ, Berrios GE, et al. 2000. A brief cognitive test battery to differentiate Alzheimer’s disease and frontotemporal dementia. Neurology . 55:1613–1620. doi:10.1212/01.wnl.0000434309.85312.19
doi: 10.1212/01.wnl.0000434309.85312.19
Meola G, Biasini F, Valaperta R, et al. 2017. Biomolecular diagnosis of myotonic dystrophy type 2: a challenging approach. J Neurol. 264:1705–1714. doi:10.1007/s00415-017-8504-1
doi: 10.1007/s00415-017-8504-1
Meola G, Sansone V, Perani D, et al. 2003. Executive dysfunction and avoidant personality trait in myotonic dystrophy type 1 (DM-1) and in proximal myotonic myopathy (PROMM/DM-2). Neuromuscul Disord. 13:813–821. doi:10.1016/s0960-8966(03)00137-8
doi: 10.1016/s0960-8966(03)00137-8
Messinis L, Kosmidis MH, Nasios G, et al. 2020. Do secondary progressive multiple sclerosis patients benefit from computer-based cognitive neurorehabilitation? A randomized sham controlled trial [published online January 7]. Mult Scler Relat Disord. 39:101932. doi:10.1016/j.msard.2020.101932
doi: 10.1016/j.msard.2020.101932
Minnerop M, Weber B, Schoene-Bake J-C, et al. 2011. The brain in myotonic dystrophy 1 and 2: evidence for a predominant white matter disease. Brain. 134(pt 2):3530–3546. doi:10.1093/brain/awr299
doi: 10.1093/brain/awr299
Nasreddine ZS, Phillips NA, Bédirian V, et al. 2005. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 53:695–699. doi:10.1111/j.1532-5415.2005.53221.x
doi: 10.1111/j.1532-5415.2005.53221.x
Newman B, Meola G, O’Donovan DG, et al. 1999. Proximal myotonic myopathy (PROMM) presenting as myotonia during pregnancy. Neuromuscul Disord. 9:144–149. doi:10.1016/s0960-8966(98)00118-7
doi: 10.1016/s0960-8966(98)00118-7
Okkersen K, Buskes M, Groenewoud J, et al. 2017. The cognitive profile of myotonic dystrophy type 1: a systematic review and meta-analysis. Cortex. 95:143–155. doi:10.1016/j.cortex.2017.08.008
doi: 10.1016/j.cortex.2017.08.008
Omer T, Finegan E, Hutchinson S, et al. 2017. Neuroimaging patterns along the ALS–FTD spectrum: a multiparametric imaging study. Amyotroph Lateral Scler Frontotemporal Degener. 18:611–623. doi:10.1080/21678421.2017.1332077
doi: 10.1080/21678421.2017.1332077
Peric S, Bozovic I, Nisic T, et al. 2019. Body composition analysis in patients with myotonic dystrophy types 1 and 2. Neurol Sci. 40:1035–1040. doi:10.1007/s10072-019-03763-0
doi: 10.1007/s10072-019-03763-0
Peric S, Brajkovic L, Belanovic B, et al. 2017a. Brain positron emission tomography in patients with myotonic dystrophy type 1 and type 2. J Neurol Sci. 378:187–192. doi:10.1016/j.jns.2017.05.013
doi: 10.1016/j.jns.2017.05.013
Peric S, Mandic-Stojmenovic G, Stefanova E, et al. 2015. Frontostriatal dysexecutive syndrome: a core cognitive feature of myotonic dystrophy type 2. J Neurol. 262:142–148. doi:10.1007/s00415-014-7545-y
doi: 10.1007/s00415-014-7545-y
Peric S, Rakocevic Stojanovic V, Mandic Stojmenovic G, et al. 2017b. Clusters of cognitive impairment among different phenotypes of myotonic dystrophy type 1 and type 2. J Neurol Sci. 38:415–423. doi:10.1007/s10072-015-2778-4
doi: 10.1007/s10072-015-2778-4
Prouskas SE, Chiaravalloti ND, Kant N, et al. 2019. Cognitive rehabilitation in patients with advanced progressive multiple sclerosis: possible within limits? Paper presented at: European Committee for Treatment and Research in Multiple Sclerosis; September 11–13, 2019; Stockholm, Sweden.
Romeo V, Pegoraro E, Ferrati C, et al. 2010. Brain involvement in myotonic dystrophies: neuroimaging and neuropsychological comparative study in DM1 and DM2. J Neurol. 257:1246–1255. doi:10.1007/s00415-010-5498-3
doi: 10.1007/s00415-010-5498-3
Sansone V, Gandossini S, Cotelli M, et al. 2007. Cognitive impairment in adult myotonic dystrophies: a longitudinal study. Neurol Sci. 28:9–15. doi:10.1007/s10072-007-0742-z
doi: 10.1007/s10072-007-0742-z
Sansone V, Meola G, Perani D, et al. 2006. Glucose metabolism and dopamine PET correlates in a patient with myotonic dystrophy type 2 and parkinsonism. J Neurol Neurosurg Psychiatry. 77:425–426. doi:10.1136/jnnp.2005.078451
doi: 10.1136/jnnp.2005.078451
Schneider-Gold C, Bellenberg B, Prehn C, et al. 2015. Cortical and subcortical grey and white matter atrophy in myotonic dystrophies type 1 and 2 is associated with cognitive impairment, depression and daytime sleepiness [published online June 26]. PloS One. 10:e0130352. doi:10.1371/journal.pone.0130352
doi: 10.1371/journal.pone.0130352
Strauss E, Sherman EMS, Spreen O, et al. 2006. A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary. 3rd ed. New York, New York: Oxford University Press.
Udd B, Krahe R. 2012. The myotonic dystrophies: molecular, clinical, and therapeutic challenges. Lancet Neurol. 11:891–905. doi:10.1016/S1474-4422(12)70204-1
doi: 10.1016/S1474-4422(12)70204-1
Udd B, Krahe R, Wallgren-Pettersson C, et al. 1997. Proximal myotonic dystrophy—a family with autosomal dominant muscular dystrophy, cataracts, hearing loss and hypogonadism: heterogeneity of proximal myotonic syndromes? Neuromuscul Disord. 7:217–228. doi:10.1016/s0960-8966(97)00041-2
doi: 10.1016/s0960-8966(97)00041-2
Weber YG, Roebling R, Kassubek J, et al. 2010. Comparative analysis of brain structure, metabolism, and cognition in myotonic dystrophy 1 and 2. Neurology. 74:1108–1117. doi:10.1212/WNL.0b013e3181d8c35f
doi: 10.1212/WNL.0b013e3181d8c35f
Wenninger S, Montagnese F, Schoser B. 2018. Core clinical phenotypes in myotonic dystrophies [published online May 2]. Front Neurol. 9:303. doi:10.3389/fneur.2018.00303
doi: 10.3389/fneur.2018.00303
Zalonis I, Bonakis A, Christidi F, et al. 2010. Toward understanding cognitive impairment in patients with myotonic dystrophy type 1. Arch Clin Neuropsychol. 25:303–313. doi:10.1093/arclin/acq016
doi: 10.1093/arclin/acq016